Robert W. Baird analyst Eric Coldwell maintained a Buy rating on AmerisourceBergen (NYSE:ABC) on Tuesday, setting a price target of $156, which is approximately 33.92% above the present share price of $116.49.
Coldwell expects AmerisourceBergen to post earnings per share (EPS) of $2.12 for the third quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Moderate Buy rating of shares in AmerisourceBergen, with an average price target of $138.8.
The analysts price targets range from a high of $156 to a low of $122.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $49.15 billion and a net profit of $702.5 million. The company's market cap is $24.16 billion.
According to TipRanks.com, Robert W. Baird analyst Eric Coldwell is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 14.1% and a 63.04% success rate.
AmerisourceBergen Corp. engages provision of pharmaceutical products and business solutions that improve access to care. It operates through the Pharmaceutical Distribution Services and Other segments. The Pharmaceutical Distribution Services segment distributes a comprehensive offering of brand-name, specialty brand-name & generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies & equipment, outsourced compounded sterile preparations, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent & chain retail pharmacies, mail order pharmacies, medical clinics, long-term care & alternate site pharmacies, and other customers. The Other segment focuses on global commercialization services and animal health and includes ABCS, World Courier, and MWI. The company was founded in 1947 and is headquartered in Chesterbrook, PA.